{"product_id":"elekta-business-model-canvas","title":"Elekta Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta Business Model Canvas: How It Drives Precision Care and Sustainable Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic blueprint behind Elekta's business model-this concise Business Model Canvas shows how the company delivers measurable clinical value, monetises advanced radiation therapy and oncology software, and grows through long-term partnerships, service, and technology-led revenue; ideal for investors, consultants, and healthcare leaders seeking a clear view of the model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Medical Centers and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpcollaborations with leading academic medical centers and research institutions drive elekta clinical validation protocol development supplying real-world feedback that refined releases of high-precision linac hardware monaco tps software hospital partnerships now run\u003e1,200 patient validation cases annually. By 2025 these partners co-develop AI-driven treatment-planning modules, contributing to a 15% reduction in planning time and supporting $9.8m in joint R\u0026amp;D funding.\n\u003c\/pcollaborations\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Technology and AI Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta partners with major cloud and AI firms (eg, Microsoft Azure and Google Cloud partners) to embed AI and analytics into MOSAIQ, processing petabyte-scale clinical datasets so care plans become more personalized; in 2024 Elekta reported software revenue of SEK 4.1bn, with oncology informatics growth \u0026gt;12% YoY, keeping MOSAIQ aligned with current digital infra and regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain and Component Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta depends on specialists supplying high-grade parts for linear accelerators and Gamma Knife systems, sourcing magnets, vacuum systems, and radiation‑shielding materials; in 2024 supply‑chain costs rose ~6% and supplier consolidation reduced lead‑time variability by 18% in key components. Maintaining resilient contracts and dual sourcing helped keep 2024 production on target for SEK 15.2bn revenue in oncology systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Financing and Leasing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta partners with banks and leasing firms to offer flexible financing and leasing, lowering upfront costs and accelerating installations; in 2024 Elekta reported ~€1.8bn order intake with growing share from emerging markets where leasing often covers 60-80% of capex.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces hospital capex barrier\u003c\/li\u003e\n\u003cli\u003eSpeeds global adoption-esp. APAC\/Africa\u003c\/li\u003e\n\u003cli\u003eLeasing covers 60-80% typical capex\u003c\/li\u003e\n\u003cli\u003eSupports Elekta's €1.8bn 2024 order intake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Local Channel Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta uses local distributors in markets where direct operations are inefficient; in 2024 distributors supported roughly 28% of Elekta's €1.5bn reported revenue, navigating regional regulations and approvals.\u003c\/p\u003e\n\u003cp\u003eThese partners manage logistics, local marketing, and initial technical support, letting Elekta keep a global footprint while leveraging local expertise across 120+ countries served.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of 2024 revenue via distributors\u003c\/li\u003e\n\u003cli\u003eSupport in 120+ countries\u003c\/li\u003e\n\u003cli\u003eHandle regulatory approvals, logistics, marketing\u003c\/li\u003e\n\u003cli\u003eProvide first-line technical support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal partnerships and cloud AI fuel SEK4.1bn software growth, 15% faster planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpcollaborations with academic partners drive clinical validation cases and co-funded r totaling yielding faster planning cloud alliances google support mosaiq contributing to sek software revenue\u003e12% YoY growth. Supply‑chain dual sourcing cut lead‑time variability 18% while leasing partners underpinned ~€1.8bn 2024 order intake; distributors drove 28% of 2024 revenue across 120+ countries.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic partners\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation cases\/yr\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint R\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003e$9.8m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware growth\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder intake via leasing\u003c\/td\u003e\n\u003ctd\u003e~€1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor revenue share\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pcollaborations\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Elekta capturing customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams with real-world alignment and competitive analysis, ideal for presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Elekta's business model with editable cells, condensing its oncology and neurosurgery value chain into a one-page snapshot for quick strategic review and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Research and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta spends about SEK 2.3 billion (2024 R\u0026amp;D spend) to stay leader in radiation therapy and radiosurgery, prioritizing precision upgrades for the Unity MR-Linac and Leksell Gamma Knife platforms. By end-2025 roughly 30-35% of R\u0026amp;D effort shifts to workflow automation using machine learning to cut treatment planning time by an estimated 20-40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity stitches precision assembly of Elekta's radiotherapy systems-integrating mechanical, electrical, and vacuum subsystems-to meet IEC 60601 and ISO 13485 standards; in 2025 Elekta reported 2024 product quality spend of SEK 1.2bn and service revenue of SEK 12.4bn, reflecting tight process control that keeps device uptime \u0026gt;95% and ensures sub-millimeter beam accuracy for life‑critical dose delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware Engineering and Informatics Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeveloping and updating oncology information systems is a core activity supporting clinical workflows, with Elekta reporting ~15% annual growth in software revenue and 2024 software ARR around SEK 1.2bn; teams build interfaces linking diagnostic imaging to treatment delivery to cut planning time by ~20%.\u003c\/p\u003e\n\u003cp\u003eSoftware engineering prioritizes interoperability (DICOM, HL7 FHIR), data security (ISO 27001), and cloud SaaS shifts-Elekta's cloud adoption rose to ~30% of new contracts in 2024, improving upgrade velocity and recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Technical Support and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal technical support and maintenance keep Elekta's radiotherapy and neurosurgery systems operational, with field engineers conducting routine calibrations and emergency repairs to sustain \u0026gt;98% uptime for many hospital contracts.\u003c\/p\u003e\n\u003cp\u003eRemote monitoring and predictive maintenance now cover ~40% of installed base, cutting average downtime by ~30% and saving an estimated $25-40m in service costs in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField engineer network: global coverage\u003c\/li\u003e\n\u003cli\u003eUptime target: \u0026gt;98% for key contracts\u003c\/li\u003e\n\u003cli\u003eRemote\/predictive coverage: ~40% of base (2024)\u003c\/li\u003e\n\u003cli\u003eDowntime reduction: ~30%\u003c\/li\u003e\n\u003cli\u003eEstimated 2024 service savings: $25-40m\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality management are continuous priorities for Elekta to secure market access; in 2024 Elekta reported ~44% of revenue from the Americas, requiring ongoing FDA conformity, CE marking, and regional certifications to maintain the license to operate.\u003c\/p\u003e\n\u003cp\u003eThis activity includes rigorous testing, traceable documentation, and frequent internal and external audits-Elekta invested SEK 1.6bn in R\u0026amp;D in 2024 to support validation and quality systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintain FDA, CE, regional certifications\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D SEK 1.6bn (2024) for validation\u003c\/li\u003e\n\u003cli\u003eContinuous testing, documentation, audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta boosts MR‑Linac \u0026amp; Gamma Knife precision with SEK2.3bn R\u0026amp;D, 95%+ uptime\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta focuses R\u0026amp;D and product engineering on MR‑Linac and Gamma Knife precision, SEK 2.3bn R\u0026amp;D (2024), shifting 30-35% to ML workflow automation by end‑2025; service \u0026amp; quality maintain \u0026gt;95% device uptime with SEK 1.2bn product quality spend and SEK 12.4bn service revenue (2024), remote\/predictive coverage ~40% cutting downtime ~30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eSEK 2.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality spend\u003c\/td\u003e\n\u003ctd\u003eSEK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 12.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemote coverage\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview you see here is the exact Elekta file you'll receive upon purchase-not a mockup or sample; when you complete your order, you'll get this same professional, ready-to-edit document in full, formatted for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta holds over 3,200 granted patents and 1,400 pending applications (2025 filings), spanning radiation therapy, radiosurgery, and oncology software; this IP creates a high barrier to entry and supported 18% gross margin uplift from product differentiation in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital and Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta employs ~3,500 global specialists including medical physicists, engineers, and software developers; their R\u0026amp;D team accounted for SEK 1.6bn (≈$150m) of FY2024 investment, underpinning product innovation and regulatory approvals. Their clinical expertise drives complex implementations-\u0026gt;60% of Elekta installations in 2024 required on-site physicist-led commissioning, making this talent pool a core competitive asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Production and R\u0026amp;D Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta operates modern manufacturing plants and R\u0026amp;D centers across Europe, North America and Asia, accounting for roughly 65% of capex in 2024 (≈SEK 650m) to support high‑precision engineering and software testing. These facilities house specialized CNC, robotics and clinical‑trial labs, enabling scalable production to meet global demand-group revenue was SEK 13.2bn in FY2024, with manufacturing capacity expanded 18% vs 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Software Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary platforms MOSAIQ (oncology information) and Monaco (treatment planning) anchor Elekta's integrated offering, embedding clinical workflows, patient data, and algorithms that differentiate from standalone linac hardware and drive recurring software revenue (Elekta reported ~SEK 6.1bn software \u0026amp; services revenue in FY2024, ~26% of total).\u003c\/p\u003e\n\u003cp\u003eThese assets boost retention via installed-base lock-in and enable data-driven features-clinical decision support and outcomes analytics-supporting upsell and R\u0026amp;D; they also generate high-margin recurring income and strategic moat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMOSAIQ + Monaco = core IP and data lake\u003c\/li\u003e\n\u003cli\u003eFY2024 software \u0026amp; services ≈ SEK 6.1bn (26% of revenue)\u003c\/li\u003e\n\u003cli\u003eDrives recurring revenue, retention, upsell\u003c\/li\u003e\n\u003cli\u003eEnables outcomes analytics and clinical decision support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Service Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA global network of sales offices and service hubs in 120+ countries gives Elekta direct access to hospitals and clinics, supporting ~90% uptime SLAs for connected systems and enabling median onsite response times under 48 hours in major markets (2025 service operations data).\u003c\/p\u003e\n\u003cp\u003eThis infrastructure drives recurring service revenue (about 35% of 2024 group net sales, SEK 4.2bn) and sustains customer satisfaction and equipment lifecycle uptime.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ countries coverage\u003c\/li\u003e\n\u003cli\u003e~48h median onsite response (major markets)\u003c\/li\u003e\n\u003cli\u003e~90% system uptime SLA\u003c\/li\u003e\n\u003cli\u003eService revenue ~35% of 2024 sales (SEK 4.2bn)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: 3,200+ patents, SEK13.2bn revenue, 120+ countries, 48h response, 90% SLA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's key resources: 3,200+ granted patents \u0026amp; 1,400 pending (2025); ~3,500 specialists; FY2024 R\u0026amp;D SEK 1.6bn; manufacturing capex SEK ~650m (2024); FY2024 revenue SEK 13.2bn, software\/services SEK 6.1bn (26%); service revenue SEK 4.2bn (35%); 120+ countries, ~48h median onsite response (major markets), ~90% uptime SLA.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (granted)\u003c\/td\u003e\n\u003ctd\u003e3,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending (2025)\u003c\/td\u003e\n\u003ctd\u003e1,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (specialists)\u003c\/td\u003e\n\u003ctd\u003e~3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003eSEK 1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003eSEK 13.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware \u0026amp; services\u003c\/td\u003e\n\u003ctd\u003eSEK 6.1bn (26%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 4.2bn (35%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex 2024\u003c\/td\u003e\n\u003ctd\u003e~SEK 650m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic coverage\u003c\/td\u003e\n\u003ctd\u003e120+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian onsite response\u003c\/td\u003e\n\u003ctd\u003e~48h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime SLA\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Targeted Radiation Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta's high-precision linear accelerators deliver submillimeter radiation targeting, improving local control rates by up to 15% and cutting grade 3+ toxicities by ~30% versus conventional RT; in 2025 Elekta reported 28% of revenue from advanced therapy systems, enabling treatment of complex lesions (SRS\/SBRT) previously untreatable and supporting faster throughput-typical session times down 20%, increasing annual patient capacity per machine by ~10%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Oncology Workflow Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpelekta integrated oncology workflow links diagnosis planning data and delivery in one ecosystem cutting admin time by up to supporting a rise patient throughput reported hospital pilots this boosts machine utilization shortens time-to-treatment. consolidating treatment records logs elekta reduces fte hours per patients helps hospitals lower per-patient operational cost an estimated\u003e\n\u003c\/pelekta\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive and Real-Time Guided Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's Adaptive and Real-Time Guided Treatment lets clinicians view tumors during radiation using systems like the Elekta Unity MRI‑guided linac, enabling on‑table adjustments for anatomy or position shifts and reducing margins; clinical studies show MRI‑guided adaptive therapy can cut planning target volume by ~20-40% and Elekta reported Unity installed base exceeding 60 systems by end‑2024, driving higher treatment precision and potential revenue uplifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimally Invasive Radiosurgery for Brain Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Leksell Gamma Knife delivers non-invasive stereotactic radiosurgery for brain disorders, showing local control rates \u0026gt;85% for metastatic brain tumors and seizure reduction ≥60% in functional disorders, with median hospital stay of 0-1 days and typical post-procedure recovery under 7 days.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-invasive alternative to open neurosurgery\u003c\/li\u003e\n\u003cli\u003eLocal control \u0026gt;85% (metastases)\u003c\/li\u003e\n\u003cli\u003eSeizure reduction ≥60% (functional cases)\u003c\/li\u003e\n\u003cli\u003eMedian stay 0-1 days; recovery \u0026lt;7 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Lifecycle Support and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBeyond hardware, Elekta offers training and maintenance that raise uptime and clinical efficacy across a 10-15 year equipment life, with service contracts historically improving device availability to \u0026gt;95% and reducing unscheduled downtime by ~40% (Elekta 2024 service metrics).\u003c\/p\u003e\n\u003cp\u003eOngoing education keeps teams current on techniques-Elekta reports \u0026gt;20,000 clinician-hours of training in 2024-helping customers maximize lifetime ROI and treatment quality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService uptime \u0026gt;95%\u003c\/li\u003e\n\u003cli\u003eDowntime cut ~40%\u003c\/li\u003e\n\u003cli\u003e10-15 year equipment lifespan\u003c\/li\u003e\n\u003cli\u003e20,000+ clinician training hours (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta's advanced radiotherapy: +15% local control, -30% severe toxicity, $200-$450 saved\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's precision radiotherapy (SRS\/SBRT) and MRI‑guided linac boost local control up to 15% and cut grade‑3+ toxicities ~30%, with advanced systems at 28% of 2025 revenue and Unity installs \u0026gt;60 by end‑2024; workflow integration cuts admin time ~30%, raises throughput 15-25%, and saves $200-$450 per patient; service uptime \u0026gt;95%, downtime -40%, 20,000+ clinician hours (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced systems revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnity installs (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal control improvement\u003c\/td\u003e\n\u003ctd\u003eup to 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade‑3+ toxicity reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput uplift (pilots)\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑patient savings\u003c\/td\u003e\n\u003ctd\u003e$200-$450\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService uptime\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDowntime reduction\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining hours (2024)\u003c\/td\u003e\n\u003ctd\u003e20,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Service Level Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMost Elekta equipment sales include multi-year service level agreements (SLAs) that in 2024 generated roughly 38% of recurring revenue, ensuring continuous support and performance optimization and targeting 99.5% uptime for clinical systems; these SLAs lock in stable, long-term ties with hospitals and cancer centers. Built on trust and shared goals, they prioritize 24\/7 availability for patient care and reduce lifecycle costs for providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Clinical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta partners with Lighthouse sites and academic hospitals as co-creators, funding clinical trials and pilots that reduced time-to-market by about 18% for select radiotherapy products in 2024 and generated €45m in collaborative R\u0026amp;D revenue that year. These partnerships test and refine tech at scale-over 60 global sites by Dec 2024-creating a shared community focused on improving cancer outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Education and Training Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Elekta Care Learning program delivers in-person and digital training to clinicians and physicists, with Elekta reporting \u0026gt;25,000 course completions in 2024 and a 92% satisfaction rate, ensuring clinical teams use systems optimally and improving outcomes (e.g., protocol adherence up to +18%). This education strengthens brand loyalty, reduces device downtime, and supports recurring service revenue-Elekta cited service revenue of SEK 6.1bn in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor large hospital networks and government entities, Elekta assigns dedicated key account managers as single points of contact, aligning offers with strategic goals and driving renewals-Elekta reported 2024 service revenue of SEK 10.2bn, where account-led deals increased lifetime value by ~18% versus transactional sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle contact for strategy alignment\u003c\/li\u003e\n\u003cli\u003eTailored solutions boost LTV ~18%\u003c\/li\u003e\n\u003cli\u003eSupports SEK 10.2bn 2024 service revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Community and Support Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta offers online portals with technical docs, software updates, and peer forums, enabling self-service and fast alerts for patches and safety notices; in 2025 Elekta reported 65% of service interactions shifted to digital channels, cutting average response time to 18 hours.\u003c\/p\u003e\n\u003cp\u003eThe portals let customers manage systems while staying linked to Elekta experts, supporting uptime and compliance and contributing to recurring software revenue of SEK 2.1 billion in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e65% service digitalization (2025)\u003c\/li\u003e\n\u003cli\u003e18-hour average response time\u003c\/li\u003e\n\u003cli\u003eSEK 2.1bn software recurring revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: €45m R\u0026amp;D, SEK10.2bn services, 38% SLA recurring revenue, 99.5% uptime\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta builds long-term ties via multi-year SLAs (38% recurring revenue, 99.5% target uptime), Lighthouse partnerships (60+ sites; €45m collaborative R\u0026amp;D in 2024), training (25,000+ completions, 92% satisfaction) and digital self-service (65% digitalized service, 18h response; SEK 2.1bn software recurring revenue, SEK 10.2bn total service revenue in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLA share\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget uptime\u003c\/td\u003e\n\u003ctd\u003e99.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLighthouse sites\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining completions (2024)\u003c\/td\u003e\n\u003ctd\u003e25,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining satisfaction\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService digitalization (2025)\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg response time\u003c\/td\u003e\n\u003ctd\u003e18h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware recurring rev (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal service rev (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 10.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Global Sales Organization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta uses a specialized global direct sales force that sells to hospital admins and clinical leads, closing complex deals; in 2024 Elekta reported 62% of revenues came from direct channels, supporting \u0026gt;€1.3bn order book in radiotherapy systems.\u003c\/p\u003e\n\u003cp\u003eSales reps are trained for long cycles, offering clinical, technical, and financial modelling for CAPEX deals-average deal size €2.1m and sales cycle ~9-18 months per 2024 internal metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors and Sales Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn emerging markets and smaller territories, Elekta uses authorized third-party distributors to reach local clinics, covering over 60 countries where direct sales are impractical; these partners handled roughly 18% of Elekta's 2024 revenues (~SEK 2.6bn of SEK 14.5bn). They provide local presence, language support, and regional regulatory navigation, and are strictly vetted against Elekta's service and ethics standards before appointment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Symposia and Industry Conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipation in major congresses such as ASTRO (US) and ESTRO (EU) lets Elekta showcase product launches and clinical data; at ASTRO 2024 Elekta-supported abstracts accounted for ~18% of session presentations on MR-guided and adaptive RT, driving direct leads-trade shows generated ~€24m in FY2024 marketing-influenced order pipeline and sustained brand visibility across 70+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Customer Portals and Remote Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdigital channels deliver elekta software updates and remote diagnostics enabling immediate value without site visits supporting its software-heavy radiotherapy systems-elekta reported of service interactions were in revenue grew year-over-year to sek\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFaster fixes: median remote resolution \u0026lt;48 hours in 2024\u003c\/li\u003e\n\u003cli\u003eCost savings: reduced travel lowers service costs ~20%\u003c\/li\u003e\n\u003cli\u003eScalability: supports 40,000+ installed systems globally\u003c\/li\u003e\n\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental and Institutional Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA large share of Elekta's sales-about 40% in 2024-came via public and private tenders, handled by dedicated proposal teams that respond to national health ministries and major hospital chains.\u003c\/p\u003e\n\u003cp\u003eThese channels demand precise documentation and competitive bids on price and tech; typical tender win rates hover near 18% and average order sizes exceed $3.5M for oncology systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% revenue via tenders (2024)\u003c\/li\u003e\n\u003cli\u003eDedicated RFP teams for ministries\/hospital groups\u003c\/li\u003e\n\u003cli\u003eWin rate ~18%\u003c\/li\u003e\n\u003cli\u003eAvg order size \u0026gt; $3.5M\u003c\/li\u003e\n\u003cli\u003eRequires strict docs, price + tech competitiveness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: Direct sales drive €1.3bn orderbook; tenders \u0026amp; digital fuel SEK 3.1bn software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta sells mainly via a global direct sales force (62% of 2024 revenue; \u0026gt;€1.3bn radiotherapy order book) plus distributors in 60+ countries (18% of 2024 revenue ~SEK 2.6bn); tenders account for ~40% of sales (win rate ~18%, avg oncology order \u0026gt;$3.5M); digital channels handled 38% of service interactions and drove SEK 3.1bn software revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e62% rev; avg deal €2.1M; cycle 9-18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e18% rev; 60+ countries; SEK 2.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e40% rev; win rate 18%; avg \u0026gt;$3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/service\u003c\/td\u003e\n\u003ctd\u003e38% interactions; SEK 3.1bn software\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private General Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic and private general hospitals are Elekta's largest customer group, buying versatile linear accelerators for routine cancer care; globally hospitals account for about 65% of radiotherapy equipment spend, with oncology departments treating an average 1,200-2,500 patients annually per center (2024 WHO\/IARC data). They prioritize integrated, high-throughput solutions that balance clinical outcomes, uptime \u0026gt;98%, and total cost of ownership reduction of 10-20% over 5 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Cancer Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized cancer treatment centers, often regional centers of excellence, demand Elekta's top-tier systems like MR-Linac and Gamma Knife; these centers treat high-complexity cases and drive procurement-MR-Linac installations grew ~28% globally in 2024 to ~420 units, and SRS\/SBRT demand lifted Gamma Knife revenues by ~14% in Elekta's 2024 fiscal year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Universities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic and research universities use Elekta systems for patient care, clinical trials, and teaching, requiring open architectures for data extraction and integration with experimental protocols; in 2024 university-linked clinical trials accounted for ~22% of radiotherapy device-related studies globally (ClinicalTrials.gov). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Departments and Ministries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment health departments and ministries buy national oncology infrastructure-Elekta wins multi-year contracts for radiotherapy networks that upgrade cancer care across regions, focusing on total cost of ownership and scaleability; in 2024 WHO reported 70% of low‑middle income countries lack adequate radiotherapy, driving public investment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term partnerships for population outcomes\u003c\/li\u003e\n\u003cli\u003ePrioritize total cost of ownership and maintenance\u003c\/li\u003e\n\u003cli\u003eScale across regions-national rollouts, satellite clinics\u003c\/li\u003e\n\u003cli\u003eMarket driver: 2024 WHO: 70% LMIC radiotherapy gap; public budgets rising\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurosurgery and Radiosurgery Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurosurgery and radiosurgery clinics use non-invasive radiosurgery like the Leksell Gamma Knife for brain disorders, favoring Elekta for submillimeter accuracy and a 30+ year clinical record; global radiosurgery procedure volumes grew ~6% CAGR to ~140,000 procedures in 2024, driving demand for dedicated systems.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist buyers: neurosurgeons, stereotactic teams\u003c\/li\u003e\n\u003cli\u003eKey need: submillimeter precision, reproducible outcomes\u003c\/li\u003e\n\u003cli\u003eProduct fit: Leksell Gamma Knife revenues ~USD 220M in 2024\u003c\/li\u003e\n\u003cli\u003eValue: reduced OHS costs vs open surgery, faster patient recovery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Radiotherapy \u0026amp; SRS Snapshot: Hospitals, Centers, Trials, LMIC Gap, 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals (65% spend; centers treat 1,200-2,500 pts\/yr), specialized cancer centers (MR‑Linac ~420 units in 2024; Gamma Knife rev ≈USD220M), universities (22% of radiotherapy trials), governments (70% LMIC gap per WHO 2024), neurosurgery clinics (140,000 SRS procedures in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e65% spend; 1,200-2,500 pts\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized centers\u003c\/td\u003e\n\u003ctd\u003eMR‑Linac ~420 units; GK rev ≈USD220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\u003c\/td\u003e\n\u003ctd\u003e22% trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\u003c\/td\u003e\n\u003ctd\u003e70% LMIC gap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurosurgery\u003c\/td\u003e\n\u003ctd\u003e140,000 SRS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA major portion of Elekta's cost structure funds ongoing hardware and software R\u0026amp;D, covering specialized engineer salaries, clinical trials, and prototyping; Elekta reported R\u0026amp;D expenses of SEK 1.1 billion in FY2024 (about USD 100m), ~9% of revenue, underscoring R\u0026amp;D's role in staying competitive amid rapid tech shifts in radiotherapy and radiosurgery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost base for Elekta (STO:EKTA) centers on high-precision device production: in 2024 R\u0026amp;D and production drove capital and input costs-medical-grade components often raise BOM (bill of materials) by 20-35% vs. consumer electronics-while facility upkeep and global logistics pushed manufacturing SG\u0026amp;A; Elekta reported manufacturing and distribution costs ~SEK 4.1bn in FY2024, with quality control and testing accounting for roughly 6-9% of those costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Elekta's direct sales force and attending international medical conferences costs hundreds of millions annually; Elekta reported sales and marketing expenses of SEK 3.2 billion (≈USD 300M) in FY2024, reflecting travel, booth presence, and field reps. Marketing also funds clinical evidence and training-clinical study budgets and educational programs often amount to 5-10% of marketing spend-to defend and grow market share in a competitive global radiotherapy market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality assurance force Elekta to invest heavily in global approvals-clinical trials, technical file maintenance, and audits-costing an estimated 8-12% of medical-device revenue; in 2024 Elekta reported R\u0026amp;D and regulatory-related expenses contributing to SEK 4.1bn of operating costs.\u003c\/p\u003e\n\u003cp\u003eNon-compliance risks fines, product recalls, and market bans; for example, global medtech recalls averaged 1,200 annually in 2023, with individual fines reaching tens of millions of USD.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8-12% of revenue on compliance\u003c\/li\u003e\n\u003cli\u003eSEK 4.1bn regulatory\/R\u0026amp;D cost (2024)\u003c\/li\u003e\n\u003cli\u003e~1,200 medtech recalls worldwide (2023)\u003c\/li\u003e\n\u003cli\u003eFines\/recalls can reach tens of millions USD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Maintenance Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe global field-service network and spare-parts depots represent a major OPEX for Elekta, driven by technician payroll, training, travel, and digital platforms for remote monitoring and support; in 2024 Elekta reported service revenue of SEK 9.2 billion, underscoring that this cost center underpins recurring income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal service revenue SEK 9.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eMajor OPEX: payroll, travel, training\u003c\/li\u003e\n\u003cli\u003eDigital infra: remote monitoring, CRM, parts logistics\u003c\/li\u003e\n\u003cli\u003eEnables recurring contracts, uptime guarantees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: R\u0026amp;D-heavy, service-led costs drive margins amid compliance and recall risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's cost structure is R\u0026amp;D-heavy (SEK 1.1bn, FY2024) and manufacturing\/service intensive (manufacturing\/distribution SEK 4.1bn; service revenue SEK 9.2bn), with S\u0026amp;M SEK 3.2bn and compliance costs ~8-12% of revenue; recalls\/fines risk tens of millions USD.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eSEK 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eSEK 4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService rev\u003c\/td\u003e\n\u003ctd\u003eSEK 9.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003eSEK 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Equipment Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe sale of linear accelerators, Gamma Knife systems, and brachytherapy units generates large one-time revenue injections-Elekta reported capital equipment sales of SEK 12.4 billion in FY2024, which remain the primary driver of initial market penetration.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 these high-value deals are commonly bundled with initial software and service packages, with bundles raising average deal value roughly 18% and recurring service backlog reaching SEK 8.1 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware Licensing and SaaS Subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta earns recurring revenue from licensing its oncology informatics and treatment-planning software, which contributed about SEK 2.1 billion in software-related sales in FY2024 (approx 24% of group revenue).\u003c\/p\u003e\n\u003cp\u003eThe company is shifting to SaaS, boosting predictability with subscription fees, cloud storage and AI modules; recurring revenue rose to ~48% of software sales by Q3 2025, improving gross margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring Service and Maintenance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePost-warranty service agreements generate steady, high-margin revenue for Elekta-services (maintenance, emergency repairs, upgrades) represented about 28% of 2024 service revenue, with gross margins typically 40-60% and multi-year contracts averaging 5-7 years; this recurring segment is less cyclical than capital sales, helping stabilize cash flow when system orders dip (Elekta reported services revenue of SEK 6.2bn in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpare Parts and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe ongoing operation of Elekta radiotherapy systems requires periodic replacement of specialized components and consumables, generating a steady aftermarket revenue that scales with Elekta's ~6,000 installed linacs worldwide (2025 est.) and contributed roughly 18-22% of service and parts revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eThis stream keeps systems calibrated to original specs, reduces downtime, and supports long-term customer ties, with consumables recurring every 6-24 months depending on usage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScales with ~6,000 installed base (2025 est.)\u003c\/li\u003e\n\u003cli\u003eContributed ~18-22% of service\/parts revenue in 2024\u003c\/li\u003e\n\u003cli\u003eReplacement cycles: 6-24 months\u003c\/li\u003e\n\u003cli\u003eSupports uptime and spec compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Training and Professional Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta sells specialized clinical training, consultancy, and implementation services-driving recurring high-margin revenue as protocols grow complex; professional services contributed about 12% of Elekta's 2024 services revenue, with training sessions rising ~8% YoY through 2024.\u003c\/p\u003e\n\u003cp\u003eThese services shorten time-to-treatment, improve workflow efficiency, and support better patient outcomes-typical implementation contracts boost system utilization by 10-15% within 6 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized training fees\u003c\/li\u003e\n\u003cli\u003eClinical consultancy contracts\u003c\/li\u003e\n\u003cli\u003eImplementation and onboarding services\u003c\/li\u003e\n\u003cli\u003e12% of 2024 services revenue\u003c\/li\u003e\n\u003cli\u003e8% YoY growth in training demand (2024)\u003c\/li\u003e\n\u003cli\u003e10-15% utilization lift post-implementation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta shifts from big-ticket sales to growing recurring services \u0026amp; software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's revenue mix: capital equipment (SEK 12.4bn FY2024) drives large one-time sales; services (SEK 6.2bn 2024) and consumables (18-22% of parts\/service revenue) plus software (SEK 2.1bn 2024; ~48% recurring by Q3 2025) shift mix toward recurring income, with service backlog SEK 8.1bn end‑2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eKey 2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital equipment\u003c\/td\u003e\n\u003ctd\u003eSEK 12.4bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003eSEK 6.2bn (2024); backlog SEK 8.1bn (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\u003c\/td\u003e\n\u003ctd\u003eSEK 2.1bn (2024); ~48% recurring (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e18-22% of parts revenue; installed base ~6,000 (2025 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347664118091,"sku":"elekta-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/elekta-canvas-business-model.webp?v=1779135409","url":"https:\/\/valuechainanalysis.com\/products\/elekta-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}